Randomized Controlled Trial of Developmental Reciprocity Treatment in Young Children with Autism.

J Autism Dev DisordJun 9, 2025 (epub)
Clinical ResearchPediatricsPsychiatryOpen access

Grace W Gengoux, Katherine Paszek, Maria Estefania Millan et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled 24-week pilot trial compared Developmental Reciprocity Treatment, combining parent training and direct child treatment, with delayed treatment in 37 children aged 2–5 years with autism spectrum disorder and language delay. By 24 weeks, 83% of parents in the intervention group met implementation-fidelity criteria. Controlling for fidelity, the intervention group showed greater improvement on the Social Responsiveness Scale Total Score (F = 5.00; p = 0.034) and the Clinical Global Impressions Improvement scale. No significant group differences were found on three other communication or adaptive-function measures.

Key findings

  • By 24 weeks, 83% of parents receiving Developmental Reciprocity Treatment met fidelity-of-implementation criteria.
  • Controlling for fidelity, the intervention group improved more on the Social Responsiveness Scale Total Score (F = 5.00; p = 0.034).
  • Greater improvement was also reported on the Clinical Global Impressions Improvement scale, but not on the other three assessed measures.

Why it matters

The trial provides preliminary evidence that a developmentally based intervention combining parent training with direct child treatment may improve some aspects of social functioning in young children with autism and language delay. The mixed results across outcome measures underscore that gains in social responsiveness do not necessarily extend to observed communication, adaptive behaviour, or reported language development.

What to keep in mind

This was a pilot trial with 37 children and 24 weeks of follow-up; significant group differences were not observed across all measured outcomes.

Source

Published in J Autism Dev Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.